Liraglutide (Generic Saxenda)

Liraglutide is a prescription weight loss injection containing liraglutide, an active ingredient that suppresses appetite and increases feelings of fullness. It mimics a natural hormone called glucagon-like peptide-1 (GLP-1), which helps regulate hunger signals in the brain. This effect helps individuals consume fewer calories and achieve sustainable weight loss. Liraglutide is licensed for weight management in the UK and is recommended alongside a balanced diet and regular exercise for the best results.

Saxenda® (liraglutide) is a GLP-1 receptor agonist and was the first FDA-approved medication in this class for weight management. It is approximately 97% similar to the naturally occurring GLP-1 hormone, which is released after eating to help regulate appetite. Unlike native GLP-1, which has a very short half-life of around 2 minutes, Saxenda® has a longer half-life of approximately 13 hours, allowing for sustained activity when administered by daily injection. It works by acting on GLP-1 receptors in the brain, particularly in the hypothalamus, to increase feelings of fullness (satiety) and reduce hunger signals, which leads to reduced food intake and gradual weight loss when combined with lifestyle changes.

Clinical studies show that patients can lose up to 5% after 12 weeks when following the recommended dosing schedule of GLP-1 receptor agonists, although individual responses can vary. Clinical evidence also suggests that age significantly influences treatment outcomes, with older individuals generally experiencing less weight reduction compared to younger patients. For example, in a meta-analysis of placebo-controlled trials involving liraglutide, participants aged around 30 years lost approximately 10.1 kg over 52 weeks, whereas those aged around 60 years lost about 3.3 kg over the same period. This difference is thought to be due to age-related physiological changes, including a reduced basal metabolic rate, loss of muscle mass leading to lower energy expenditure, and hormonal changes that affect fat metabolism. As a result, patient age should be taken into account when evaluating the effectiveness of GLP-1 therapies, and it is an important factor to consider in both clinical assessment and the design of weight management studies.

Liraglutide is a self-administered injection that comes in a pre-filled pen. Your doctor will prescribe an increasing dose schedule, which gradually increases the medication to help your body adjust.

How to Inject Liraglutide:

1. Prepare the pen by attaching a new needle. Ensure the solution is clear and free from particles.
2. Check the flow by performing a dose test before the first injection from a new pen.
3. Select the prescribed dose using the dial on the pen.
4. Inject the medication into the skin of the stomach, thigh, or upper arm, holding for a few seconds before removing the needle.
5. Dispose of the needle safely and store the pen correctly for future use.

Your doctor or pharmacist will provide detailed guidance on how to administer the injection properly.

Like all medications, Liraglutide can cause side effects, but not everyone will experience them.

Common side effects (affecting up to 1 in 10 people):

• Nausea, vomiting, or indigestion.
• Stomach discomfort, bloating, or heartburn.
• Injection site reactions such as redness, irritation, or mild swelling.
• Feeling weak or dizzy.
• Changes in taste.

Less common side effects:

• Dehydration due to vomiting or diarrhoea.
• Gallbladder inflammation or gallstones.
• Increased heart rate.
• General feelings of being unwell.

Rare side effects:

• Kidney problems or acute kidney failure.
• Severe constipation leading to bowel obstruction.

Most side effects reduce as the body adjusts to the medication. If you experience persistent or severe symptoms, seek medical advice.

Liraglutide is not suitable for everyone, and certain conditions may require alternative treatments.

Do NOT take Liraglutide if you:

• Have severe heart failure or kidney disease.
• Are pregnant, breastfeeding, or planning to conceive.
• Are under 18 or over 75 years old (limited safety data available).
• Have gut or stomach problems, such as gastroparesis or inflammatory bowel disease.
• Are due for surgery requiring anaesthesia.

Drug Interactions

Liraglutide may interact with certain medications, including:

• Blood thinners (e.g., warfarin) – May affect clotting times.
• Diabetes medications (e.g., sulfonylureas like glimepiride) – May increase the risk of low blood sugar (hypoglycaemia).

Always inform your doctor about any medications you are currently taking before starting Liraglutide.